ABSTRACT
Sequencing of CETP in Māori and Pacific peoples identified a common (MAF ∼2.4%-5.4%) population-specific missense variant (rs1597000001, CETP:c.530C>T p.Pro177Leu) that associates with higher HDL-C levels (
[95% CI 0.211; 0.260]) and lower LDL-C (
[95% CI -0.209; -0.058]). In a subsample of the study cohort (n = 11), heterozygous carriers of the population-specific variant had lower plasma CETP activity (P = 0.028). Our study identifies a population-specific missense variant in CETP which lowers CETP activity with an effect on HDL-C that is comparable to Mendelian CETP loss-of-function mutations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ML was funded by an HRC Māori Postdoctoral Fellowship. JM was funded by an HRC Pacific PhD scholarship. The work was funded by the National Institute of Health grants R01HL093093 (STM), R01HL133040 (RLM), R01AG09375 (STM), R01HL52611 (MI Kamboh), R01DK59642 (STM), and R01DK55406 (RD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the Aotearoa NZ cohort study was given by the NZ Multi-Region Ethics Committee (MEC/05/10/130; MEC/10/09/092; MEC/11/04/036), the Northern Y Region Health Research Ethics Committee (Ngāti Porou Hauora Charitable Trust study; NTY07/07/074), and the University of Otago Human Health Ethics Committee (Pacific Trust Otago; 12/349). Ethical approval for the Samoan I cohort study was given by the Health Research Committee of the Samoa Ministry of Health and the institutional review board of Brown University. Ethical approvals for the Samoan II and III cohort studies were given by the Health Research Committee of the Samoa Ministry of Health and the Institutional Review Boards (IRBs) of the Department of Health in American Samoan; of The Miriam Hospital, Providence, Rhode Island; and of Brown University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data from the Aotearoa NZ and PTO cohorts are not publicly available owing to consent restrictions but can be requested from the corresponding author under an appropriate arrangement. Samoan cohort I data are available from dbGaP (accession number: phs000914.v1.p1). Samoan II and III cohort data (recruited in 2002 to 2003 and 1990 to 1995, respectively) are not available as participants were not consented for data sharing.
